drugset / Trial / NCT07307261

Evaluation of Mirabegron Versus Tamsulosin or Their Combination in Treatment of Lower Urinary Tract Symptoms

NCT07307261

Completed 300 enrolled Avraiem Talaat
RandomizedParallel-groupOpen-labelTreatment

Summary

Stent related symptoms (SRSs) comprise of complaints such as irritative symptoms, sense of incomplete emptying, flank and suprapubic pain, and incontinence. Mechanical irritation of trigone, urinary reflux, and stent movement are plausible causes for SRSs. Alpha-blockers are the primary medications for ureteral stent-related symptoms. These medications are suggested to patients by the American Urological Association (AUA)/Endourological Society guideline to reduce stent-related symptoms with moderate recommendation. Nevertheless, there are many side effects associated with alpha-blockers such as dizziness, headache, and orthostatic hypotension

Timeline

Start
2024-10-10
Primary completion
2025-10-05
Completion
2025-10-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 50 mg
Comparator Tamsulosin Other / unclassified 0.4 mg

Indications

No indication recorded.